Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 03/12/07 → 01/9/10 |
Funding
- Pfizer Incorporated: $2,400.00
A Randomized Phase II Study of the Efficacy and Safety of Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing as First-Line Therapy for Metastatic Renal Cell Cancer (Renal EFFECT Trial)
- Wu, Shenhong (PI)
- Madajewicz, Stefan (PI)
Project: Research